| Ticker Details |
Gilead Sciences, Inc.
Gilead Sciences Inc is a biopharmaceutical company that discovers, develops and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases.
|
| IPO Date: |
January 3, 1994 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$166.82B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.76 | 1.14%
|
| Avg Daily Range (30 D): |
$1.48 | 1.10%
|
| Avg Daily Range (90 D): |
$1.72 | 1.24%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
7.25M |
| Avg Daily Volume (30 D): |
4.07M |
| Avg Daily Volume (90 D): |
4.71M |
| Trade Size |
| Avg Trade Size (Sh.): |
135 |
| Avg Trade Size (Sh.) (30 D): |
56 |
| Avg Trade Size (Sh.) (90 D): |
59 |
| Institutional Trades |
| Total Institutional Trades: |
124,055 |
| Avg Institutional Trade: |
$5.54M |
| Avg Institutional Trade (30 D): |
$18.93M |
| Avg Institutional Trade (90 D): |
$20.27M |
| Avg Institutional Trade Volume: |
.12M |
| Avg Institutional Trades (Per Day): |
21 |
| Market Closing Trades |
| Avg Closing Trade: |
$59.12M |
| Avg Closing Trade (30 D): |
$158.84M |
| Avg Closing Trade (90 D): |
$195.4M |
| Avg Closing Volume: |
859.71K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$7.42
|
$1.63
|
$1.76
|
|
Diluted EPS
|
$7.34
|
$1.61
|
$1.74
|
|
Revenue
|
$29.74B
|
$6.96B
|
$7.93B
|
|
Gross Profit
|
$23.6B
|
$5.52B
|
$6.3B
|
|
Net Income / Loss
|
$9.22B
|
$2.02B
|
$2.18B
|
|
Operating Income / Loss
|
$10.37B
|
$2.59B
|
$1.98B
|
|
Cost of Revenue
|
$6.14B
|
$1.45B
|
$1.62B
|
|
Net Cash Flow
|
$-298M
|
$64M
|
$234M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Jan 28, 2013
|
2:1
|
|
Jun 25, 2007
|
2:1
|
|
Sep 07, 2004
|
2:1
|
|
Mar 08, 2002
|
2:1
|
|
Feb 22, 2001
|
2:1
|
|
|
|
